China Trends To Watch: Reform And Approvals Accelerate, Costs Slow
This article was originally published in The Tan Sheet
From increasing new drug approval efficiency to pricing relaxation to allowing physicians to work in multiple locations, more regulatory changes are coming in China, which is likely to make 2015 a volatile year for drug makers in the country.
You may also be interested in...
A regulatory pathway set up in China post-SARS is under stress test in the latest coronavirus outbreak, while emergency measures adopted by the country's regulator mean it’s much less burdensome to obtain approvals than before.
In a drastic move, China sends top physicians from around the country to Wuhan, finally allows a WHO expert delegation to visit hospitals in the outbreak's epicenter and welcomes foreign experts.